Assertio Therapeutics Inc

ASRT stock touches 52-week low at $0.68 amid market challenges

Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock has reached a new 52-week low, dipping to $0.68, as investors navigate a tumultuous market environment. With a market capitalization...

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive...

Assertio stock price target cut to $3.50 at H.C. Wainwright

On Wednesday, H.C. Wainwright analyst Raghuram Selvaraju adjusted the price target for Assertio Therapeutics (NASDAQ:ASRT) to $3.50, down from the previous $4.00, while maintaining...

Depomed receives Investment Bank Analyst Rating Update

ASRT stock touches 52-week low at $0.68 amid market challenges

Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock has reached a new 52-week low, dipping to $0.68, as investors navigate a turbulent market environment. According to InvestingPro...

Earnings call transcript: Assertio Q4 2024 beats revenue expectations

Assertio Holdings reported its Q4 2024 earnings, surpassing revenue forecasts with $32.18 million against the expected $28.67 million. The company also reported a...

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year...

Assertio Therapeutics earnings beat by $0.01, revenue topped estimates

Investing.com - Assertio Therapeutics (NASDAQ: ASRT) reported first quarter EPS of $-0.0300, $0.01 better than the analyst estimate of $-0.0400. Revenue for the quarter came in at...

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT) today announced that it will release fourth quarter and...

Assertio Holdings faces Nasdaq delisting over share price rule

Assertio Holdings, Inc. (NASDAQ:ASRT), a pharmaceutical company currently trading at $0.81 per share, is confronting potential delisting from the Nasdaq Capital Market due to...